menu
    • menu
    [{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"AM0010","moa":"IL-10 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"},{"orgOrder":0,"company":"ARMO BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"IL-10 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"ARMO BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMO BioSciences \/ ARMO BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"ARMO BioSciences \/ ARMO BioSciences"}]

    Find Clinical Drug Pipeline Developments & Deals by ARMO BioSciences

    Menu

    ARMO BioSciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 11, 2019

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AM0010

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Expanded Access Program for AM0010 (Pegilodecakin)

                            Details : AM0010 is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 13, 2018

                            Lead Product(s) : AM0010

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Partici...

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 26, 2017

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants W...

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 26, 2017

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY35...

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 22, 2017

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 30, 2017

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Me...

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 05, 2016

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            ARMO BioSciences

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

                            Details : Pegilodecakin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 12, 2013

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth